Currently, there are 208.54M common shares owned by the public and among those 197.13M shares have been available to trade.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The company’s stock has a 5-day price change of 0.36% and 10.80% over the past three months. BCRX shares are trading 10.51% year to date (YTD), with the 12-month market performance up to 47.60% higher. It has a 12-month low price of $4.03 and touched a high of $9.50 over the same period. BCRX has an average intraday trading volume of 2.72 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -4.83%, 2.62%, and 10.39% respectively.
Institutional ownership of Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) shares accounts for 78.46% of the company’s 208.54M shares outstanding.
It has a market capitalization of $1.74B and a beta (3y monthly) value of 1.73. The earnings-per-share (ttm) stands at -$0.43. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.26% over the week and 4.98% over the month.
Earnings per share for the fiscal year are expected to increase by 82.88%, and 413.58% over the next financial year.
Looking at the support for the BCRX, a number of firms have released research notes about the stock. Wedbush stated their Outperform rating for the stock in a research note on February 25, 2025, with the firm’s price target at $15. JP Morgan coverage for the Biocryst Pharmaceuticals Inc (BCRX) stock in a research note released on November 20, 2023 offered a Overweight rating with a price target of $10. RBC Capital Mkts was of a view on September 18, 2023 that the stock is Outperform, while Jefferies gave the stock Buy rating on August 04, 2023, issuing a price target of $11. BofA Securities on their part issued Buy rating on July 13, 2023.
